{"entity":{"id":"nct06516289","kind":"trial","name":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06516289 as recruiting, last updated 2024-12-12. Enrolment is 130 planned participants, an estimate. Interventions: HRS-1167, Famitinib, Camrelizumab. Primary measures include Safety run-in: Incidence rate of dose-limiting toxicities (DLTs); Safety run-in: adverse events (AEs). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06516289","url":"https://clinicaltrials.gov/study/NCT06516289"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["hrs-1167"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06516289","phase":"2","setting":"Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib/ HRS-1167, Famitinib and Camrelizumab: A Prospective, Open-label, Multicenter, Phase II Trial","sponsor":"Fudan University","started":"2024-09-30","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06516289/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"hrs-1167","kind":"drug","name":"HRS-1167","route":"/drugs/hrs-1167/"}]}}